vTv Therapeutics (NASDAQ:VTVT) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06, Fidelity Earnings reports. The company had revenue of $3.38 million during the quarter, compared to the consensus estimate of $2.06 million.

NASDAQ VTVT opened at $2.63 on Friday. vTv Therapeutics has a 12 month low of $0.65 and a 12 month high of $8.40. The stock has a market capitalization of $91.52 million, a price-to-earnings ratio of -1.57 and a beta of -3.71.

Separately, Zacks Investment Research lowered vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $13.29.

In related news, major shareholder Ronald O. Perelman purchased 1,879,699 shares of vTv Therapeutics stock in a transaction on Thursday, September 27th. The shares were purchased at an average price of $1.33 per share, for a total transaction of $2,499,999.67. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders acquired a total of 5,644,097 shares of company stock worth $7,504,999 in the last quarter. Corporate insiders own 2.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “vTv Therapeutics (VTVT) Announces Earnings Results” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/11/10/vtv-therapeutics-vtvt-announces-earnings-results.html.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Featured Article: Bond

Earnings History for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.